N. Vardakis

892 total citations
33 papers, 762 citations indexed

About

N. Vardakis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, N. Vardakis has authored 33 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in N. Vardakis's work include Cancer Treatment and Pharmacology (20 papers), Lung Cancer Treatments and Mutations (14 papers) and Colorectal Cancer Treatments and Studies (12 papers). N. Vardakis is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Lung Cancer Treatments and Mutations (14 papers) and Colorectal Cancer Treatments and Studies (12 papers). N. Vardakis collaborates with scholars based in Greece, Kuwait and United States. N. Vardakis's co-authors include Vassilis Georgoulias, John Souglakos, N. Androulakis, Sofia Agelaki, Αthanasios Kotsakis, Kostas Kalbakis, D. Mavroudis, S. Kakolyris, Dora Hatzidaki and Stylianos Kakolyris and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

N. Vardakis

32 papers receiving 723 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Vardakis Greece	17	629	416	163	108	94	33	762
Lambros Vamvakas Greece	17	597 0.9×	370 0.9×	114 0.7×	49 0.5×	71 0.8×	44	759
Tarek Chidiac United States	11	802 1.3×	384 0.9×	207 1.3×	187 1.7×	102 1.1×	16	1.0k
D. Turci Italy	14	492 0.8×	250 0.6×	74 0.5×	120 1.1×	109 1.2×	43	637
L. Cals France	15	495 0.8×	253 0.6×	79 0.5×	80 0.7×	109 1.2×	41	674
A. Chemaissani Germany	9	464 0.7×	508 1.2×	124 0.8×	39 0.4×	72 0.8×	13	650
Arpine Gevorgyan Italy	10	404 0.6×	236 0.6×	148 0.9×	72 0.7×	72 0.8×	24	546
L. Vamvakas Greece	12	693 1.1×	351 0.8×	105 0.6×	209 1.9×	102 1.1×	48	807
C. Blajman Argentina	9	446 0.7×	425 1.0×	186 1.1×	26 0.2×	180 1.9×	15	759
Thierry Nguyen France	15	281 0.4×	203 0.5×	93 0.6×	67 0.6×	159 1.7×	40	613
A. Reinacher-Schick Germany	11	441 0.7×	146 0.4×	175 1.1×	88 0.8×	93 1.0×	46	636

Countries citing papers authored by N. Vardakis

Since Specialization

Citations

This map shows the geographic impact of N. Vardakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Vardakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Vardakis more than expected).

Fields of papers citing papers by N. Vardakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Vardakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Vardakis. The network helps show where N. Vardakis may publish in the future.

Co-authorship network of co-authors of N. Vardakis

This figure shows the co-authorship network connecting the top 25 collaborators of N. Vardakis. A scholar is included among the top collaborators of N. Vardakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Vardakis. N. Vardakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Soultati, Aspasia, Stylianos Giassas, N. Vardakis, et al.. (2012). Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. Cancer Chemotherapy and Pharmacology. 70(1). 161–168. 23 indexed citations

Souglakos, John, N. Vardakis, N. Androulakis, et al.. (2012). Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial.. PubMed. 10(1). 47–52.

Kotsakis, Αthanasios, Eleni‐Kyriaki Vetsika, Dora Hatzidaki, et al.. (2011). Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Annals of Oncology. 23(2). 442–449. 44 indexed citations

Xenidis, Nikolaos, Αthanasios Kotsakis, A. Kalykaki, et al.. (2009). Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Lung Cancer. 68(3). 450–454. 5 indexed citations

Pallis, Athanasios, Sofia Agelaki, S. Kakolyris, et al.. (2008). Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel–gemcitabine chemotherapy. Lung Cancer. 62(3). 356–363. 42 indexed citations

Kakolyris, Stylianos, John Souglakos, Aris Polyzos, et al.. (2008). Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy. Oncology. 74(1-2). 31–36. 4 indexed citations

Pallis, Athanasios, Sofia Agelaki, L. Vamvakas, et al.. (2006). Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial. Lung Cancer. 55(1). 101–107. 4 indexed citations

Souglakos, John, A. Kalykaki, L. Vamvakas, et al.. (2006). Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Annals of Oncology. 18(2). 305–310. 56 indexed citations

Kotsakis, Αthanasios, Ch. Kouroussis, N. Androulakis, et al.. (2006). A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors. Oncology. 71(3-4). 190–196. 3 indexed citations

10.

Souglakos, John, Konstantinos Syrigos, Anna Potamianou, et al.. (2004). Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Annals of Oncology. 15(8). 1204–1209. 41 indexed citations

11.

Kakolyris, Stylianos, John Souglakos, Ch. Kouroussis, et al.. (2004). Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors. Oncology. 66(4). 253–259. 2 indexed citations

12.

Mavroudis, D., Periklis Pappas, Ch. Kouroussis, et al.. (2003). A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Annals of Oncology. 14(2). 304–312. 32 indexed citations

13.

Mavroudis, D., M. Veslemes, F Apostolopoulou, et al.. (2002). Sequential administration of cisplatin–etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Lung Cancer. 39(1). 71–76. 11 indexed citations

14.

Kouroussis, Charalambos, John Souglakos, Dimitris Mavroudis, et al.. (2002). Oxaliplatin With High-Dose Leucovorin and Infusional 5-Fluorouracil in Irinotecan-Pretreated Patients With Advanced Colorectal Cancer (ACC). American Journal of Clinical Oncology. 25(6). 627–631. 10 indexed citations

15.

Kakolyris, S., Ch. Kouroussis, Michael I. Koukourakis, et al.. (2002). A Dose-Escalation Study of Oxaliplatin and Vinorelbine in Patients with Advanced Solid Tumors. Oncology. 63(3). 213–218. 6 indexed citations

16.

Mavroudis, Dimitriοs, Stylianos Kakolyris, John Souglakos, et al.. (2001). A phase I study of the caelyx - oxaliplatin combination in patients with advanced solid tumors. European Journal of Cancer. 37. S75–S76. 1 indexed citations

17.

Kakolyris, S., Ch. Kouroussis, John Souglakos, et al.. (2001). A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors. Oncology. 61(4). 265–270. 4 indexed citations

18.

Kouroussis, Ch., Sofia Agelaki, D. Mavroudis, et al.. (2000). A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 46(6). 488–492. 21 indexed citations

19.

Mavroudis, Dimitriοs, Sofia Agelaki, Kostas Kalbakis, et al.. (1999). A dose finding and toxicity study of the gemcitabine-oxaliplatin combination in patients with advanced solid tumors. European Journal of Cancer. 35. S289–S290. 1 indexed citations

20.

Androulakis, N., Charalambos Kouroussis, S. Kakolyris, et al.. (1998). Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study. Annals of Oncology. 9(10). 1127–1130. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact